Related Experiment Video
Updated: Mar 6, 2026
08:55
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
19.1K
Pituitary dysfunction in childhood after [177Lu]Lu-DOTATATE therapy
Karen van Wessel1, Bart de Keizer2,3, Miranda P Dierselhuis2
1Wilhelmina Children's Hospital, Utrecht, The Netherlands.
Journal of Pediatric Endocrinology & Metabolism : JPEM
|March 4, 2026
Summary
This study reports the first case of pituitary dysfunction, including growth hormone deficiency and central hypothyroidism, after [177Lu]Lu-DOTATATE therapy for neuroblastoma. Early screening for pituitary issues is recommended for children undergoing this treatment.
Area of Science:
- Pediatric Oncology
- Endocrinology
- Nuclear Medicine
Background:
- Neuroblastoma treatment with chemotherapy and [131I]MIBG can cause endocrine issues.
- Peptide receptor radionuclide therapy using [177Lu]Lu-DOTATATE targets somatostatin receptors in neuroblastoma.
- No endocrine effects were previously reported for [177Lu]Lu-DOTATATE in children.
